Key Points
- Director John Thomas sold 10,000 shares on March 2 at an average price of $2.90 for $29,000, trimming his stake by 2.03% to 482,784 shares (valued at about $1.4M).
- Analysts are mixed: MarketBeat lists a consensus rating of Moderate Buy with an average price target of $21.00, while recent reports include three Buy ratings and at least one Sell.
- The stock has a market cap of $98.17M, 50‑/200‑day moving averages of $3.01/$4.23 and a one‑year range of $1.99–$8.53, and about 37.33% institutional ownership after several hedge funds established or increased positions.
Genelux Corporation (NASDAQ:GNLX - Get Free Report) Director John Thomas sold 10,000 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $2.90, for a total transaction of $29,000.00. Following the completion of the transaction, the director directly owned 482,784 shares in the company, valued at $1,400,073.60. This trade represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Genelux Price Performance
NASDAQ GNLX opened at $2.58 on Wednesday. The company has a fifty day moving average of $3.01 and a two-hundred day moving average of $4.23. The company has a market capitalization of $98.17 million, a PE ratio of -2.93 and a beta of 0.15. Genelux Corporation has a 1 year low of $1.99 and a 1 year high of $8.53.
Wall Street Analyst Weigh In
GNLX has been the topic of several research analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Genelux in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Genelux from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. Finally, HC Wainwright reiterated a "buy" rating on shares of Genelux in a research report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Genelux presently has a consensus rating of "Moderate Buy" and an average price target of $21.00.
View Our Latest Stock Analysis on GNLX
Hedge Funds Weigh In On Genelux
A number of hedge funds and other institutional investors have recently bought and sold shares of GNLX. Goldman Sachs Group Inc. purchased a new position in Genelux during the 1st quarter worth $239,000. Jane Street Group LLC acquired a new position in shares of Genelux during the first quarter worth about $190,000. Geode Capital Management LLC lifted its position in Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company's stock valued at $915,000 after purchasing an additional 5,596 shares during the period. MAI Capital Management boosted its holdings in Genelux by 66,161.3% in the 2nd quarter. MAI Capital Management now owns 236,553 shares of the company's stock valued at $679,000 after purchasing an additional 236,196 shares in the last quarter. Finally, Private Management Group Inc. acquired a new position in Genelux during the 2nd quarter worth approximately $33,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.
About Genelux
(
Get Free Report)
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company's programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux's lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.
Genelux's pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
